Drug Profile
PS 948115
Alternative Names: PS-948115Latest Information Update: 22 Mar 2010
Price :
$50
*
At a glance
- Originator Pharmacopeia
- Developer Merck & Co
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory tract disorders
Most Recent Events
- 25 Sep 2007 Phase-I clinical trials in Respiratory tract disorders in USA (unspecified route)
- 11 Apr 2006 Preclinical trials in Respiratory tract disorders in USA (unspecified route)